Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;24(7):837-9.
doi: 10.1111/j.1468-3083.2009.03202.x. Epub 2009 Apr 2.

Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases

K Ibler  1 , T N Dam, R Gniadecki, K Kragballe, G B E Jemec, T Agner
Affiliations

Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases

K Ibler et al. J Eur Acad Dermatol Venereol. 2010 Jul.

Abstract

Background: Efalizumab is a recombinant humanized murine monoclonal antibody against CD11a, approved for the treatment of plaque psoriasis. However, recent reports suggest that it also may be effective in the treatment of severe atopic dermatitis (AD).

Objective: To evaluate the clinical effect of efalizumab in AD.

Methods: A systematic retrospective study of the medical files of patients treated with efalizumab for AD in Danish dermatology departments. Positive outcome was defined as improvement of the disease registered in the patient's file over a period exceeding 6 months.

Results: Two of eleven patients had a positive outcome. Nine patients stopped treatment due to progression of AD or lack of effect.

Limitations: Retrospective study.

Conclusions: Only a minority of patients with severe AD responded to efalizumab treatment in a standard dose.

PubMed Disclaimer

LinkOut - more resources